On Tuesday, June 25th, the U.S. Food and Drug Administration ("FDA") responded to the New Drug Application that Acer Therapeutics submitted to bring celiprolol (under the brand name Edsivo) to the U.S. as a treatment for vascular Ehlers-Danlos Syndrome ("vEDS"). In the response, the FDA declined the application, requesting a new trial to demonstrate the impact of celiprolol in vEDS. We will make a series of posts that discuss the future of vEDS treatments, but we don't believ

In April 2019, an observational study of vascular EDS was published in the Journal of American College of Cardiology (link). The good news i

As our subscribers saw in our recent post, the University of Washington is hosting a meeting of the vEDS Collaborative on July 27, 2018. For those registered to participate via video or phone, we wanted to share a brief post to let you know what to expect. For those who are unfamiliar with the meeting, or want to register to listen in, please visit our 2018 vEDS Collaborative Meeting Page for more details. Introducing the vEDS Collaborative and its Mission In 2017, researcher